On 23 September, the European Medicines Agency (EMA) recommended that the marketing authorisations for medicines containing rosiglitazone be suspended (Avandia, Avandamet and Avaglim). This means these medicines will stop being available in Europe within a few months. After a review of all the data about cardiovascular risk, the EMA concluded that the benefits no longer outweigh the risks.
The advice from the Medicines and Healthcare products Regulatory Agency (MHRA) is that patients should not stop treatment but should seek advice. Advice for healthcare professionals can be found here: it says that prescribers should “put in place a system to ensure that all patients are reviewed and changed to another suitable treatment in line with NICE recommendations.”.